Drugs / KIN-1901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04205851 | Nov 2019 → Apr 2020 | rheumatic disorder | Kinevant Sciences GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KIN-1901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04205851 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) administration of KIN-1901” NCT04205851 ↗ |